David Cooke, MD
Ophthalmology · Saint Joseph, MINPI 1942205315
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (58.8%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. Alcon Research LLC accounts for 74.9% of it on its own, with 12 other manufacturers making up the rest. 2025 is the largest year on record at $10,439, more than ten times the $1,029 reported in 2019. Among ophthalmology clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 46 payments — averaging $302.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon Research LLC$10K
- Heidelberg Engineering, Inc.$2K
- Ziemer USA$610
- Alcon$323
- AbbVie$305
- Carl Zeiss Meditec Digital Innovations LLC$136
- plus $221 from 7 others
Across 11 payments — averaging $24,306 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$255K
- Sun Pharmaceutical Industries Inc.$10K
- Perrigo Company PLC$3K
What the payments were for
- Consulting fees$8,17359%
- Speaking & faculty fees$1,93214%
- Travel & lodging$2,67419%
- Food & beverage$1,1248%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon Research LLC | 12 | $10,408 |
| Heidelberg Engineering, Inc. | 1 | $1,900 |
| Ziemer USA | 2 | $610 |
| Alcon | 11 | $323 |
| AbbVie(2 entities) | 7 | $305 |
| Carl Zeiss Meditec Digital Innovations LLC | 3 | $136 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $62 |
| Rxsight Inc | 2 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 1 | $35 |
| Ocular Therapeutix, Inc. | 1 | $29 |
| Dompe US, Inc. | 1 | $21 |
| NEW World Medical,inc. | 1 | $13 |
| Sun Pharmaceutical Industries Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Clareon$10,372
- AcrySof IQ PanOptix UV IOL$10,255
- AcrySof IQ VIVITY$10,255
- Spectralis$1,900
- XEN$216
How this compares
$13,904 in reported general payments places this provider in the 90th percentile of 674 ophthalmology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 114 | $44,730 |
| Prednisolone Acetate | 1,032 | $32,609 |
| RocklatanNetarsudil Mesylat/Latanoprost | 44 | $28,763 |
| LumiganBimatoprost | 59 | $19,890 |
| RestasisCyclosporine | 23 | $15,107 |
| Ketorolac Tromethamine | 910 | $13,832 |
| Restasis MultidoseCyclosporine | 13 | $13,176 |
| Latanoprost | 1,049 | $12,541 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 51 | $11,362 |
| Brinzolamide | 52 | $10,207 |
| Cyclosporine | 27 | $7,880 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 410 | $7,466 |
| Betoptic SBetaxolol Hcl | 11 | $7,079 |
| Travoprost | 42 | $6,731 |
| VyzultaLatanoprostene Bunod | 12 | $6,542 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Restasis Multidose, Alphagan P, Combigan | $305 | $56,083125 claims |
| AlconSimbrinza | $323 | $11,36251 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 674 ophthalmology providers in Michigan.
Other ophthalmology in Saint Joseph
- David BrownSaint Joseph$21K
- Manjool ShahAnn Arbor$609K
- Gregory KatzYpsilanti$401K
- Timothy PageBirmingham$250K
- David ZacksAnn Arbor$177K
- Scott WesthouseGrand Rapids$138K
- Bret HughesDetroit$123K
- Pradeepa YoganathanDetroit$115K
- Jason MillerAnn Arbor$104K
- David TukelDearborn$91K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.